Pharmacy Times

James and McPhillips unpack the everyday barriers that keep patients from addressing health concerns and make the case for at-home testing as a way around them, then turn to how pharmacists can improve their counseling once a patient shows up with results in hand.

The newly available OTC combination pairs dextromethorphan, guaifenesin, and naproxen sodium in a 12-hour formulation, creating new opportunities for pharmacist counseling on NSAID risks and duplicate therapy.

A revamped weight management program adds transparent Zepbound and Foundayo pricing, $29 MinuteClinic visits, and pharmacist support at 9000 sites.

Pharmacists can guide patients to verify sources, validate licensed pharmacies, and understand compounded versus FDA-approved products.

A new study found that first-prescription buprenorphine abandonment nearly doubled from 2020 to 2024.

Every additional access point—a pharmacist trained to screen, counsel, and, where authorized, initiate or manage therapy—is a smaller referral bottleneck.

Phase 3 SOLARIS shows high-dose vitamin D3 with first-line chemo in metastatic colorectal cancer is safe—but does not significantly improve PFS.

Patients with nodal TFHL had a 5.3% 5-year incidence of subsequent myeloid neoplasms, with shared TET2 mutations supporting divergent evolution from underlying clonal hematopoiesis.

Al-Ola Abdallah outlined the key adverse events associated with bispecific antibodies, noting that while CRS occurs in over 70% of patients, the majority of cases are grade 1 or 2 and therefore manageable in outpatient settings with appropriate infrastructure, while ICANS is less commonly observed at severe grades compared with CAR T-Cell therapy.

Learn how AIMS scoring, video tracking, and team-based follow-up boost tardive dyskinesia detection and VMAT2 treatment persistence.